About Tetratricopeptide repeat protein 31
Tetratricopeptide repeat protein 31 (TTC31) is a protein
from Homo sapiens identified by UniProt accession
Q49AM3, 519 residues long.
MolForge cross-references it against 0 known binders and
8 disease associations.
Target properties
| Protein name | Tetratricopeptide repeat protein 31 |
| UniProt accession | Q49AM3 |
| Gene | TTC31 |
| Organism | Homo sapiens |
| Length | 519 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (8)
Diseases linked to this target (Open Targets).
- platelet count · score 0.21
- platelet crit · score 0.17
- body height · score 0.07
- serum urea measurement · score 0.07
- IGF-1 measurement · score 0.06
- appendicular lean mass · score 0.03
- Stress urinary incontinence · score 0.02
- oligodendroglioma · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q49AM3-F1 | alphafold | PREDICTED | 59.99 | — |
Amino-acid sequence (519 residues)
MAPIPKTVGR IKLDCSLRPS CPLEVAAAPK LCKEFGPEDY GEEDIVDFLR RLVESDPQGL HRIHVDGSSG RLQLWHHDYL LGHLDDEGKS TGQSDRGKGA EGLGTYCGLR KSFLYPPQES EPCPQSPSAS ATFPSVSDSL LQVAMPQKLL VTEEEANRLA EELVAEEERM KQKAEKKRLK KKRQKERKRQ ERLEQYCGEP KASTTSDGDE SPPSSPGNPV QGQCGEEEDS LDLSSTFVSL ALRKVGDWPL SARREKGLNQ EPQGRGLALQ KMGQEEESPP REERPQQSPK VQASPGLLAA ALQQSQELAK LGTSFAQNGF YHEAVVLFTQ ALKLNPQDHR LFGNRSFCHE RLGQPAWALA DAQVALTLRP GWPRGLFRLG KALMGLQRFR EAAAVFQETL RGGSQPDAAR ELRSCLLHLT LQGQRGGICA PPLSPGALQP LPHAELAPSG LPSLRCPRST ALRSPGLSPL LHYPSCHRSH PNQPLSQTQS RRPHPLKPQD PSKGWDILGL GLQHLSQAR
Explore Tetratricopeptide repeat protein 31 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets